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Background: The purpose of this study was to determine if eyes with diabetic macular 
edema (DME) unresponsive to ranibizumab or bevacizumab would benefit from conversion 
to aflibercept.
Methods: This study was conducted as a retrospective chart review of subjects with DME 
unresponsive to ranibizumab and/or bevacizumab and subsequently converted to aflibercept.
Results: In total, 21 eyes from 19 subjects of mean age 62±15 years were included. The majority 
of subjects were male (63%). The median number of ranibizumab or bevacizumab injections 
before switching to aflibercept was six, and the median number of aflibercept injections after 
switching was three. Median follow-up was 5 months after the switch. Mean central foveal 
thickness (CFT) was 453.52±143.39 mm immediately prior to the switch. Morphologically, 
intraretinal cysts were present in all cases. Mean CFT after the first injection decreased signifi-
cantly to 362.57±92.82 mm (Wilcoxon signed-rank test; P,0.001). At the end of follow-up, 
the mean CFT was 324.17±98.76 mm (P,0.001). Mean visual acuity was 0.42±0.23 logMAR 
just prior to the switch, 0.39±0.31 logMAR after one aflibercept injection, and 0.37±0.22 log-
MAR at the end of follow-up. The final visual acuity was significantly better than visual acuity 
before the switch (P=0.04).
Conclusion: Eyes with DME unresponsive to multiple ranibizumab/bevacizumab injections 
demonstrate anatomical and visual improvement on conversion to aflibercept.
Keywords: diabetic retinopathy, macular edema, aflibercept, bevacizumab, ranibizumab
Introduction
Diabetic retinopathy is a major cause of visual loss worldwide, with vision-threatening 
diabetic retinopathy being present in 10% of people with diabetes. Diabetic macular 
edema (DME) is the main cause of visual impairment in diabetic retinopathy, and 
there is ample evidence for the role of vascular endothelial growth factor (VEGF) in 
the pathogenesis of DME.1–6 Several large clinical trials have established the impor-
tant role of the anti-VEGF agents, ranibizumab and bevacizumab, in the treatment 
of DME.7–12
Aflibercept is a novel anti-VEGF agent composed of the VEGF-binding portions 
of the extracellular domains of human VEGF receptors 1 and 2 fused to the Fc portion 
of human immunoglobulin G1. Aflibercept functions as a soluble decoy receptor. The 
DA VINCI, VISTA, and VIVID studies have established that treatment with afliber-
cept yields greater visual gains than macular laser treatment, and the drug has since 
received US Food and Drug Administration approval for this indication.13–15 A recent 
trial has also demonstrated that aflibercept is superior to ranibizumab or bevacizumab 
for eyes with DME and poorer presenting acuity.
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Currently, many patients who have received ranibizumab 
or bevacizumab for the treatment of DME and who have 
failed to respond to these drugs are being switched to afliber-
cept. Differences in the pharmacodynamics of aflibercept 
compared with ranibizumab or bevacizumab have been the 
basis of this strategy. Unlike ranibizumab, aflibercept binds 
VEGF with much greater affinity and also binds placen-
tal growth factor. Some patients may also be switched to 
aflibercept due to its reportedly longer duration of action. 
There are currently few data on the outcomes following this 
therapeutic switch. Retrospective data from subjects receiv-
ing this treatment for age-related macular degeneration have 
suggested that anatomical improvement with less significant 
visual improvement can be expected.
The aim of this study was to evaluate the short-term out-
comes following conversion from ranibizumab or bevacizumab 
therapy to aflibercept for the treatment of refractory DME.
Materials and methods
This was a retrospective series of patients treated at two 
tertiary eye care centers, ie, Singapore National Eye Centre 
and Massachusetts Eye and Ear Infirmary. Subjects were 
identified from electronic medical records using the appro-
priate International Classification of Diseases and billing 
codes. Subjects were included if they had been treated for 
DME with ranibizumab and/or bevacizumab and were sub-
sequently converted to aflibercept between September 2012 
and September 2014. Exclusion criteria included other visu-
ally significant ocular pathology and complications of dia-
betic retinopathy (eg, tractional retinal detachment, vitreous 
hemorrhage), loss to follow-up, fewer than three ranibizumab 
and/or bevacizumab injections prior to conversion to afliber-
cept, and incomplete imaging or clinical data.
Patient demographics, systemic comorbidities, and 
patients’ diabetes control (HbA
1c 
levels) were recorded. The 
main outcomes of note were the best-corrected visual acuity, 
which was recorded as Snellen visual acuity and converted 
to logMAR equivalents for analysis, and the anatomical 
changes as documented on optical coherence tomography. 
Spectral-domain optical coherence tomography was per-
formed using the Cirrus (Carl Zeiss Meditec, Dublin, CA, 
USA) or Spectralis (Heidelberg Engineering, Heidelberg, 
Germany) platforms. The main optical coherence tomogra-
phy measures of note were central foveal thickness (CFT) 
as well as the presence of intraretinal or subretinal fluid on 
the tomogram. The CFT values were automatically gener-
ated by the imaging software and used in the analyses after 
the tomograms had been reviewed for segmentation errors. 
In cases where segmentation errors were seen, the CFT was 
manually measured from the tomogram showing the greatest 
foveal elevation. Intraretinal or subretinal fluid was classified 
dichotomously as either present or absent, with cases in which 
only trace fluid was seen (very fine intraretinal cysts or very 
thin slivers of subretinal fluid) being classified as absent.
The study complied with the Health Insurance Portability 
and Accountability Act of 1996 and was performed in accor-
dance with the tenets of the Declaration of Helsinki as revised 
in 1989. This was an observational, retrospective, noninterven-
tional study, and approval and waiver of consent were obtained 
from the institutional review boards of both institutions.
Results
In total, 21 eyes were included from 19 subjects. Their mean 
age was 62±15 years and most were male (63%). The mean 
HbA
1c 
was 6.9%±0.7%. Of the 21 eyes, nine had received 
panretinal photocoagulation. Fifteen eyes had received focal 
laser before the switch and none after. The median number 
of ranibizumab or bevacizumab injections before switching 
to aflibercept was six, and the median number of aflibercept 
injections after switching was three. Median follow-up was 
5 months after the switch.
The mean interval between bevacizumab/ranibizumab 
injections prior to the switch was 2.4±2.2 months and the 
interval between aflibercept injections was 2.4±2.2 months 
(P=0.92). The mean CFT at presentation was 385.65±115.16 
and 431.18±147.79 µm immediately prior to the switch 
(P=0.17). Morphologically, intraretinal cysts were present 
in all cases. The mean CFT after the first aflibercept injec-
tion reduced significantly to 362.57±92.82 mm (Wilcoxon 
signed-rank test; P,0.001). At the end of follow-up, the 
mean CFT was 324.17±98.76 mm (P,0.001, Figure 1). The 
mean visual acuity was 0.42±0.23 logMAR just prior to the 
switch, 0.39±0.31 logMAR after one aflibercept injection, 
and 0.37±0.22 logMAR at the end of follow-up (Figure 2). 
The final visual acuity was significantly better compared with 
the visual acuity before the switch (P=0.04). Three of the 
21 eyes (14%) had complete resolution of intraretinal cysts 
at the end of follow-up.
A representative case is shown in Figure 3. A 78-year-old 
woman had long-standing diabetes with a recent HbA
1c
 of 
7.5%. After four bevacizumab injections, the right eye had 
persistent center-involving DME with a CFT of 516 mm 
and large cystoid spaces (Figure 3A). The CFT reduced to 
455 mm after one aflibercept injection (Figure 3B). After six 
aflibercept injections, the CFT was 357 mm and the cystoid 
spaces had resolved, although a hyperreflective clump of 
hard exudates was still seen with disruption of the ellipsoid 
zone (Figure 3C).
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Discussion
In the course of DME treatment, physicians may choose 
to switch between anti-VEGF agents for various reasons. 
Clinical reasons include the theoretically greater affinity of 
aflibercept for VEGF as well as the fact that it also binds to 
and neutralizes placental growth factor. These pharmacody-
namic differences may be particularly useful in situations 
unresponsive to ranibizumab or bevacizumab. In addition, 
physicians may choose to switch a patient to aflibercept to 
take advantage of its reportedly longer duration of action.
Anti-VEGF treatment with bevacizumab or ranibizumab 
has been clearly shown to be effective and superior to laser for 
the treatment of DME involving the foveal center. Pegaptanib 
was the first anti-VEGF agent shown to be effective in the man-
agement of DME.16 Several large trials, including the READ-2 
study,7 RESOLVE,8 and the Diabetic Retinopathy Clinical 
Research (DRCR) Network group studies,9,10 have shown 
anti-VEGF treatment with bevacizumab or ranibizumab to be 
superior to laser alone. Despite these encouraging results with 
anti-VEGF agents, some cases either do not respond at all to 
ranibizumab or bevacizumab, or demonstrate an initial response 
to treatment followed by subsequent nonresponse to further 
treatment or during disease reactivation. Various mechanisms 
may underlie this loss of therapeutic effect. Pharmacodynamic 
mechanisms include increased VEGF expression from inflam-
matory cells and upregulation of VEGF receptors, while phar-
macokinetic tolerance represents an immune response to the 
anti-VEGF antibodies injected leading to rapid clearance. In 
these cases, other agents may be used to suppress VEGF. For 
example, an intravitreal dexamethasone implant (Ozurdex®) has 
been shown to be effective in eyes unresponsive to treatment 
with bevacizumab or ranibizumab.17
More recently, aflibercept has likewise been shown to 
be effective in the treatment of center-involving DME, pro-
ducing results comparable with those for ranibizumab and 
bevacizumab. The DA VINCI trial evaluated different doses 
and dosing regimens of aflibercept with laser photocoagula-
tion in eyes with DME.13,14 Patients with center-involving 
DME were assigned to either laser treatment or one of four 
aflibercept dosing groups. At 24 weeks, all the aflibercept 
groups had greater visual gains than the laser group, with 
mean improvements in acuity ranging from 8.5 to 11.4 letters 
for the aflibercept groups compared with 2.5 letters for the 
laser group. The differences were even more distinct at 52 
weeks, with letter mean gains of 9.7–12.0 in the aflibercept 
groups versus a mean letter loss of 1.3 in the laser group. 
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Figure 1 Change in mean central foveal thickness (µm).
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Figure 2 Change in mean logMar visual acuity.
Figure 3 This 78-year-old woman had long-standing diabetes with a recent HbA1c of 7.5%. 
Notes: (A) After four bevacizumab injections, the right eye had persistent center-involving diabetic macular edema with a CFT of 516 mm and large cystoid spaces. 
(B) The CFT decreased to 455 mm after one aflibercept injection. (C) After six aflibercept injections, the CFT was 357 mm and the cystoid spaces had resolved, although a 
hyperreflective clump of hard exudates was still seen with ellipsoid zone disruption.
Abbreviations: CFT, central foveal thickness; HbA1c, glycated hemoglobin.
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All the aflibercept groups also demonstrated significantly 
greater reductions in CFT compared with the laser group. The 
VISTA and VIVID trials have shown similar results, with 
aflibercept being superior to laser.18 The DRCR Network has 
recently published the results of a seminal trial comparing 
the three anti-VEGF agents for DME.19 Over 1 year, eyes 
with presenting visual acuity worse than approximately 20/50 
experienced greater visual improvement on treatment with 
aflibercept compared with bevacizumab or ranibizumab, with 
mean letter gains of 18.9 with aflibercept, 11.8 with beva-
cizumab, and 14.2 with ranibizumab. These studies suggest 
that cases unresponsive to ranibizumab and bevacizumab 
may respond instead to aflibercept.
To our knowledge, there are limited data on the results 
of switching to aflibercept after treatment with ranibizumab 
or bevacizumab for DME. Our study is limited by its small 
sample size and the inherent limitations of a retrospective 
report. Different optical coherence tomography platforms 
were also used, although each patient was always imaged 
with the same platform for follow-up scans. Nevertheless, 
significant visual and anatomical improvement with CFT 
reduction were seen after just one injection and at the end 
of follow-up. Our findings are consistent with those of the 
DRCR Network study,19 and support the notion that afliber-
cept may be more effective than ranibizumab or bevacizumab 
for more resistant cases. However, complete elimination of 
chronic cystoid spaces is difficult, and longer follow-up is 
needed to determine the effects of these lesions on vision.
Conclusion
Patients with center-involving DME who are unresponsive 
to ranibizumab or bevacizumab demonstrate anatomical 
and visual improvements after conversion to aflibercept. 
While aflibercept injections are much more costly than 
bevacizumab, the improvement that can be anticipated in 
these challenging cases suggests that making the switch is 
justifiable. Further study is warranted to determine if injec-
tion intervals can be extended with aflibercept.
Disclosure
The authors report no conflicts of interest in this work.
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